A study in BMC Neuroscience demonstrated that neprilysin gene transfer reduces amyloid‑β (Aβ) burden and improves behavioral outcomes in animal models of Alzheimer’s disease. Researchers used viral‑vector mediated delivery to increase cerebral neprilysin expression, yielding decreased plaque load and measurable cognitive benefits on behavioral assays. Authors discuss dose, distribution and long‑term expression as key translational considerations and flag potential immune responses to vectors. The data strengthen the argument for protease‑based gene therapies in Alzheimer’s and set the stage for safety and vector‑optimization studies ahead of early clinical testing.